Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBT (2023 - 2025)

CG Oncology (CGON) has disclosed EBT for 3 consecutive years, with -$41.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 29.72% year-over-year to -$41.3 million, compared with a TTM value of -$160.8 million through Dec 2025, down 82.69%, and an annual FY2025 reading of -$160.8 million, down 82.69% over the prior year.
  • EBT was -$41.3 million for Q4 2025 at CG Oncology, up from -$43.7 million in the prior quarter.
  • Across five years, EBT topped out at -$8.7 million in Q1 2023 and bottomed at -$43.7 million in Q3 2025.
  • Average EBT over 3 years is -$24.8 million, with a median of -$19.7 million recorded in 2024.
  • Peak annual rise in EBT hit 29.72% in 2025, while the deepest fall reached 119.05% in 2025.
  • Year by year, EBT stood at -$16.6 million in 2023, then crashed by 92.16% to -$31.8 million in 2024, then decreased by 29.72% to -$41.3 million in 2025.
  • Business Quant data shows EBT for CGON at -$41.3 million in Q4 2025, -$43.7 million in Q3 2025, and -$41.4 million in Q2 2025.